| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -3.3 | -1.4 |
| EPS (diluted, $ a share) | $-0.07 | $-0.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: PLYX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Polaryx Therapeutics, Inc.: key numbers
- Share price
- $1.67Close, Nov 16
- Market cap
- $83.2M
- Shares outstanding
- 49.85MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Polaryx Therapeutics, Inc.
All →Polaryx Therapeutics Shareholder Meeting
Polaryx Therapeutics held its Annual Meeting of Stockholders on September 10, 2026, where shareholders elected Alex Yang and Mitchel Berger as Class I Directors to serve until 2029. Additionally, the appointment of Grant Thornton LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.